At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
At least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.
Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollment
Must not have received immunotherapy, eg, tumor vaccines, within 42 days.
At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
At least 42 days must have elapsed after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines. Renal and Hepatic Function
At least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
